As a preliminary assessment of diffRBM performance in a cancer setting, we assigned scores to the HLA-A*02:01-presented neoantigens from the TESLA dataset (Wells et al., 2020; 11 immunogenic and 227 non-immunogenic peptides). The gene discussed is HLA-A; the disease is cancer.